Relevant bibliographies by topics / Nucleic acid drug

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Nucleic acid drug'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nucleic acid drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nucleic acid drug"

1

Veal, James M. "Nucleic acid targeted drug design." Trends in Pharmacological Sciences 14, no. 10 (October 1993): 385–86. http://dx.doi.org/10.1016/0165-6147(93)90099-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Waring, Michael J. "Nucleic acid targeted drug design." Trends in Biotechnology 12, no. 1 (January 1994): 33. http://dx.doi.org/10.1016/0167-7799(94)90009-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tan, Xuyu, Fei Jia, Ping Wang, and Ke Zhang. "Nucleic acid-based drug delivery strategies." Journal of Controlled Release 323 (July 2020): 240–52. http://dx.doi.org/10.1016/j.jconrel.2020.03.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ma, Z., and J. S. Taylor. "Nucleic acid-triggered catalytic drug release." Proceedings of the National Academy of Sciences 97, no. 21 (October 10, 2000): 11159–63. http://dx.doi.org/10.1073/pnas.97.21.11159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Takakura, Yoshinobu. "Nucleic Acid Drug Delivery and Targeting." Pharmaceutical Research 28, no. 4 (February 24, 2011): 691–93. http://dx.doi.org/10.1007/s11095-011-0394-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ashrafuzzaman, Md. "Aptamers as Both Drugs and Drug-Carriers." BioMed Research International 2014 (2014): 1–21. http://dx.doi.org/10.1155/2014/697923.

Full text
Abstract:
Aptamers are short nucleic acid oligos. They may serve as both drugs and drug-carriers. Their use as diagnostic tools is also evident. They can be generated using various experimental, theoretical, and computational techniques. The systematic evolution of ligands by exponential enrichment which uses iterative screening of nucleic acid libraries is a popular experimental technique. Theory inspired methodology entropy-based seed-and-grow strategy that designs aptamer templates to bind specifically to targets is another one. Aptamers are predicted to be highly useful in producing general drugs and theranostic drugs occasionally for certain diseases like cancer, Alzheimer’s disease, and so on. They bind to various targets like lipids, nucleic acids, proteins, small organic compounds, and even entire organisms. Aptamers may also serve as drug-carriers or nanoparticles helping drugs to get released in specific target regions. Due to better target specific physical binding properties aptamers cause less off-target toxicity effects. Therefore, search for aptamer based drugs, drug-carriers, and even diagnostic tools is expanding fast. The biophysical properties in relation to the target specific binding phenomena of aptamers, energetics behind the aptamer transport of drugs, and the consequent biological implications will be discussed. This review will open up avenues leading to novel drug discovery and drug delivery.
APA, Harvard, Vancouver, ISO, and other styles
7

Sun, Yue, Lingxian Meng, Yuxin Zhang, Dan Zhao, and Yunfeng Lin. "The Application of Nucleic Acids and Nucleic Acid Materials in Antimicrobial Research." Current Stem Cell Research & Therapy 16, no. 1 (December 1, 2021): 66–73. http://dx.doi.org/10.2174/1574888x15666200521084417.

Full text
Abstract:
Due to the misuse of antibiotics, multiple drug-resistant pathogenic bacteria have increasingly emerged. This has increased the difficulty of treatment as these bacteria directly affect public health by diminishing the potency of existing antibiotics. Developing alternative therapeutic strategies is the urgent need to reduce the mortality and morbidity related to drug-resistant bacterial infections. In the past 10 to 20 years, nanomedicines have been widely studied and applied as an antibacterial agent. They have become a novel tool for fighting resistant bacteria. The most common innovative substances, metal and metal oxide nanoparticles (NPs), have been widely reported. Until recently, DNA nanostructures were used alone or functionalized with specific DNA sequences by many scholars for antimicrobial purposes which were alternatively selected as therapy for severe bacterial infections. These are a potential candidate for treatments and have a considerable role in killing antibiotic-resistant bacteria. This review involves the dimensions of multidrug resistance and the mechanism of bacteria developing drug resistance. The importance of this article is that we summarized the current study of nano-materials based on nucleic acids in antimicrobial use. Meanwhile, the current progress and the present obstacles for their antibacterial and therapeutic use and special function of stem cells in this field are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
8

Dosio, Franco, Silvia Arpicco, Barbara Stella, and Elias Fattal. "Hyaluronic acid for anticancer drug and nucleic acid delivery." Advanced Drug Delivery Reviews 97 (February 2016): 204–36. http://dx.doi.org/10.1016/j.addr.2015.11.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Traykovska, Martina, Sjoerd Miedema, and Robert Penchovsky. "Clinical Trials of Functional Nucleic Acids." International Journal of Biomedical and Clinical Engineering 7, no. 2 (July 2018): 46–60. http://dx.doi.org/10.4018/ijbce.2018070104.

Full text
Abstract:
This chapter describes how functional nucleic acids, such as aptamers, antisense oligonucleotides (ASOs), small interfering (si) RNAs, and ribozymes are considered by some researchers as valuable tools to develop therapeutic agents. They have not been particularly fast in reaching the market as medicines, due to endogenous barriers to extracellular trafficking and cellular uptake of nucleic acids and their inherent instability when applied in vivo. However, research carried out by the nucleic acid engineering community and pharmaceutical companies to circumvent these obstacles has led to the approval of a few aptamers and ASOs as drugs. Nucleic acid therapeutics are usually administered locally to diseased tissue. The drug candidates currently in clinical trials commonly use the same administration methods as previously licensed nucleic acid therapeutics. These administration techniques carry their own safety risks and advantages. In this article, the present state is discussed and prospective options for the use ASOs and aptamers as drugs are listed.
APA, Harvard, Vancouver, ISO, and other styles
10

Mulvey, Matthew C., Margaret Lemmon, Stephanie Rotter, Jonathan Lees, Leo Einck, and Carol A. Nacy. "Optimization of a Nucleic Acid-Based Reporter System To Detect Mycobacterium tuberculosis Antibiotic Sensitivity." Antimicrobial Agents and Chemotherapy 59, no. 1 (November 3, 2014): 407–13. http://dx.doi.org/10.1128/aac.03135-14.

Full text
Abstract:
ABSTRACTWe previously reported the development of a prototype antibiotic sensitivity assay to detect drug-resistantMycobacterium tuberculosisusing infection by mycobacteriophage to create a novel nucleic acid transcript, a surrogate marker of mycobacterial viability, detected by reverse transcriptase PCR (M. C. Mulvey et al., mBio3:e00312-11, 2012). This assay detects antibiotic resistance to all drugs, even drugs for which the resistance mechanism is unknown or complex: it is a phenotypic readout using nucleic acid detection. In this report, we describe development and characteristics of an optimized reporter system that directed expression of the RNA cyclase ribozyme, which generated circular RNA through an intramolecular splicing reaction and led to accumulation of a new nucleic acid sequence in phage-infected bacteria. These modifications simplified the assay, increased the limit of detection from 104to <102M. tuberculosiscells, and correctly identified the susceptibility profile ofM. tuberculosisstrains exposed for 16 h to either first-line or second-line antitubercular drugs. In addition to phenotypic drug resistance or susceptibility, the assay reported streptomycin MICs and clearly detected 10% drug-resistant cells in an otherwise drug-susceptible population.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nucleic acid drug"

1

Slaitas, Andis. "Development of a new PNA analogue as a potential antisense drug and tool for life-science studies /." Stockholm : Karolinska institutet, 2004. http://diss.kib.ki.se/2004/91-7349-642-1/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Allsop, Julie Kay. "Development of nucleic acid vaccines for mucosal delivery." Thesis, University of Nottingham, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.263104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhou, Chenguang. "NANOCARRIERS FOR THERAPEUTIC NUCLEIC ACID DELIVERY." The Ohio State University, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=osu1336584204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

O'Daniel, Peter Ivo. "Exploring structural diversity in nucleoside and nucleic acid drug design." Diss., Available online, Georgia Institute of Technology, 2005, 2005. http://etd.gatech.edu/theses/available/etd-08252005-130946/.

Full text
Abstract:
Thesis (Ph. D.)--Chemistry and Biochemistry, Georgia Institute of Technology, 2006.
Barefield, E. Kent, Committee Member ; Beckham, Haskell W., Committee Member ; Doyle, Donald F., Committee Member ; Weck, Marcus, Committee Member ; Seley, Katherine L., Committee Chair.
APA, Harvard, Vancouver, ISO, and other styles
5

Kedge, Jonathan L. "Synthesis of ferrocene nucleic acid monomers and ferrocene containing drug candidates." Thesis, University of Birmingham, 2017. http://etheses.bham.ac.uk//id/eprint/7424/.

Full text
Abstract:
The first ferrocene nucleic acid (FcNA) was reported by the Tucker group in 2012. Furnished with two nucleobases and two hydroxyl groups, the tetrasubstituted metallocene assumes the position traditionally occupied by the two sugars of a dinucleotide. This thesis describes the successful synthesis of two FcNA monomers; a tetrasubstituted dithyminyl variation and a disubstituted control compound bearing no nucleobases. These monomers were oligomerised, their binding characteristics assessed by thermal melting studies, and compared to other monomers belonging to the group. Through the study of these compounds the Tucker group has demonstrated that FcNA monomers behave similarly to conventional nucleic acids, displaying selective H-bonding and π-stacking interactions within a hybrid duplex. A preliminary methodology for the production of diguaninyl FcNA monomers was also explored. As published in 2014, the corresponding disubstituted systems, in which a hydroxyl and a nucleobase are linked through a sugar-like ferrocene unit, are also being investigated as potential nucleoside analogues. Adding to the groups growing library, a number of related compounds were synthesised in which the hydroxyl linker length, the planar chirality, the substitution pattern of the ferrocene and the nucleobase were varied. The compounds were electrochemically characterised and assessed for their biological activity which revealed interesting structure-activity-relationships involving both the redox potentials and chirality. Following the example of ferroquine and ferrocifen, in which existing pharmaceuticals are modified through the incorporation of ferrocene, the synthesis and preliminary biological activity of novel ferrocenyl β-blockers, in which the metallocene replaces the napthol unit of the prototypical β-blocker propranolol, is reported herein.
APA, Harvard, Vancouver, ISO, and other styles
6

Garner, Mark. "Kinetic and mechanistic studies of Cisplatin derivatives with nucleic acid fragments." Thesis, University of York, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

O'Meara, Deirdre. "Molecular Tools for Nucleic Acid Analysis." Doctoral thesis, Stockholm : Tekniska högsk, 2001. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-3220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Johns, Rachel Elizabeth. "Delivery of anti-inflammatory nucleic acid therapeutics using smart polymeric carriers /." Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/8080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhou, Zhun. "Design of polymer motifs for nucleic acid recognition and assembly stabilization." The Ohio State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=osu1437558800.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Canzoneri, Joshua Craig. "Interaction of small molecules with nucleic acid targets: from RNA secondary structure to the riobosome." Diss., Georgia Institute of Technology, 2012. http://hdl.handle.net/1853/45769.

Full text
Abstract:
Nucleic acids have proven to be viable targets for small molecule drugs. While many examples of such drugs are detailed in the literature, only a select few have found practical use in a clinical setting. These currently employed nucleic acid targeting therapies suffer from either debilitating off-target side effects or succumb to a resistance mechanism of the target. The need for new small molecules that target nucleic acids is evident. However, designing a novel drug to bind to DNA or RNA requires a detailed understanding of exactly what binding environments each nucleic acid presents. In an effort to broaden this knowledge, the work presented in this thesis details the binding location and affinity of known and novel nucleic acid binding small molecules with targets ranging from simple RNA secondary structure all the way to the complex structure of ribosomal RNA. Specifically, it is shown that the anthracycline class of antineoplastics prefer to bind at or near mismatch base pairs in both physiologically relevant iron responsive element RNA hairpin constructs as well as DNA hairpin constructs presenting mismatched base pairs. Also characterized in this thesis is a novel class of topoisomerase II / histone deacetylase inhibitor conjugates that display a unique affinity for DNA over RNA. Finally, the novel class of macrolide-peptide conjugates, known as peptolides, are shown to retain potent translation inhibition of the prokaryotic ribosome. The binding pocket of the peptolides, including a crevice previously unreachable by macrolides that extends away from the peptidyl transferase center toward the subunit interface, is confirmed in detail via chemical footprinting of the 70S ribosome. Overall, the identification of a novel binding site for the anthracycline class of drugs and the characterization of the two novel drug designs presented in this thesis will undoubtedly aid in the effort to design and discover new molecules that aim for nucleic acid targets. For example, the anthracycline derivative topoisomerase II / histone deacetylase inhibitor conjugates, with their differential mode of nucleic acid binding, may prove to have a unique side effect profile in a therapeutic application. The peptolide compounds also have the potential to be applied as novel antibiotics as they bind to an area of the prokaryotic ribosome unrelated to known macrolide resistance mutations. Furthermore, as a result of the observation of this thesis work that some peptolides also posses eukaryotic translation inhibition capabilities, they could prove to be useful in preventing the growth of rapidly proliferating eukaryotic cells such as plasmodium, leishmania, or tumor cells. Additionally, different head groups could be utilized in creating new peptolides; for example, an oxazolidinone antibiotic could be employed to sample a different binding area of the ribosome.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Nucleic acid drug"

1

Methods for studying nucleic acid/drug interactions. Boca Raton: Taylor & Francis, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pullman, Bernard, and Joshua Jortner, eds. Molecular Basis of Specificity in Nucleic Acid-Drug Interactions. Dordrecht: Springer Netherlands, 1990. http://dx.doi.org/10.1007/978-94-011-3728-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Therapeutic applications of quadruplex nucleic acids. London: Elsevier/Academic Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Neidle, Stephen. Therapeutic applications of quadruplex nucleic acids. London: Elsevier/Academic Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Murakami, Akira, ed. Nucleic Acid Drugs. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-30463-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

New York Academy of Sciences. Pharmaceutical science to improve the human condition: Prix Galien 2010 : winners and finalist candidates of the Prix Galien USA, International, and Pro Bono Humanitarian Awards 2010. Malden, MA: Wiley Periodicals, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jerusalem Symposium on Quantum Chemistry and Biochemistry (23rd 1990). Molecular basis of specificity in nucleic acid-drug interactions: Proceedings of the Twenty-third Jerusalem Symposium on Quantum Chemistry and Biochemistry, held in Jerusalem, Israel, May 14-17, 1990. Dordrecht: Kluwer Academic Publishers, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhong yao cai sheng wu duo yang xing ji he suan fen xi ji shu. Beijing: Ke xue chu ban she, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Spada, Stefania. Directory of approved biopharmaceutical products. Boca Raton: CRC Press, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

service), SpringerLink (Online, ed. The Nucleolus. New York, NY: Springer Science+Business Media, LLC, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Nucleic acid drug"

1

Xiao, Wu, Chun Zhang, Preeti Yadava, and Jeffrey Hughes. "Nucleic Acid Cellular Delivery." In Cellular Drug Delivery, 81–94. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-745-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Saitoh, Shin-Ichiroh, and Kensuke Miyake. "CHAPTER 13. Nucleic Acid Innate Immune Receptors." In Drug Discovery, 292–305. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788015714-00292.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Westhof, Eric, Boris François, and Quentin Vicens. "Switchable RNA Motifs as Drug Targets." In Nucleic Acid Switches and Sensors, 107–22. Boston, MA: Springer US, 2006. http://dx.doi.org/10.1007/978-0-387-47257-7_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Franklin, T. J., and G. A. Snow. "Inhibitors of nucleic acid synthesis." In Biochemistry and Molecular Biology of Antimicrobial Drug Action, 61–76. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4757-4599-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Franklin, T. J., and G. A. Snow. "Inhibitors of nucleic acid synthesis." In Biochemistry and Molecular Biology of Antimicrobial Drug Action, 61–76. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-010-9127-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sun, Lidan, Hongwei Jin, Liangren Zhang, and Lihe Zhang. "Molecular Modeling in Nucleic Acid-Targeted Drug Design." In Medicinal Chemistry of Nucleic Acids, 258–71. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118092804.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhang, A. Yin, and Susanna Wu-Pong. "Small Nucleic Acid-Based Drugs: Successes and Pitfalls." In Biopharmaceutical Drug Design and Development, 193–221. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-532-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Antopolsky, Maxim. "Synthetic Oligonucleotides in SPECT/CT In Vivo Imaging: Chemical Modifications, In111 Complex Formation, Incorporation into Drug Delivery Systems." In Nanotechnology for Nucleic Acid Delivery, 73–82. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9092-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Takemoto, Kiichi. "Water-Soluble Nucleic Acid Analogs — Preparation and Properties." In Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems, 18–22. Tokyo: Springer Japan, 1996. http://dx.doi.org/10.1007/978-4-431-65883-2_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Crawford, Jack T. "Amplification for Detection of Mutations Imparting Drug Resistance in Mycobacteria." In Nucleic Acid Amplification Technologies Application to Disease Diagnosis, 233–43. Boston, MA: Birkhäuser Boston, 1997. http://dx.doi.org/10.1007/978-1-4612-2454-9_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nucleic acid drug"

1

Schramm, Vern L., Richard H. Furneaux, Peter C. Tyler, and Gary B. Evans. "Enzymatic transition states and drug design." In XVIth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2014. http://dx.doi.org/10.1135/css201414032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Atkin, Stephen L., Sylvain Barrier, Stephen T. Beckett, Tom Brown, Grahame Mackenzie, and Leigh Madden. "Towards the use of sporopollenin in drug delivery: Efficient encapsulation of oligonucleotides." In XIIIth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2005. http://dx.doi.org/10.1135/css200507307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Arshavsky-Graham, Sofia, Rita Vilneski, Federico Faratore, Moran Bercovici, and Ester Segal. "1,000-fold Sensitivity Enhancement of Porous Si-based Optical Biosensors for Nucleic Acid and Proteins Detection." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2017. http://dx.doi.org/10.1364/omp.2017.omm4d.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kiuru, Emilia, Mikko Ora, Leonid Beigelman, Lawrence Blatt, and Harri Lönnberg. "On the feasibility of an esterase-dependent pro-drug strategy for 2-5A." In XVth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2011. http://dx.doi.org/10.1135/css201112184.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vasilyeva, Svetlana, Nikolai Li-Zhulanov, Asya Levina, Valentina Zarytova, and Vladimir Silnikov. "Drug delivery systems based on SiO2-nanoparticles bearing covalently bound triphosphates of nucleoside analogs." In XVIth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2014. http://dx.doi.org/10.1135/css201414394.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Swarbrick, Joanna M., and Barry V. L. Potter. "Cyclic adenosine 5'-diphosphate ribose signalling: towards drug-like analogues to modulate CD38 and calcium release." In XVIth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2014. http://dx.doi.org/10.1135/css201414111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Egawa, Hiroshi, Kentaro Jingushi, Yuko Ueda, Kaori Kitae, Wataru Nakata, Kazutoshi Fujita, Motohide Uemura, Norio Nonomura, and Kazutake Tsujikawa. "Abstract A20: Innovative drug discovery for bladder cancer by miR-130 family seed-targeting locked nucleic acid." In Abstracts: AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines; December 4-7, 2015; Boston, MA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.nonrna15-a20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brown, Paige K., Ammar T. Qureshi, Daniel J. Hayes, and W. Todd Monroe. "Targeted Gene Silencing With Light and a Silver Nanoparticle Antisense Delivery System." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53647.

Full text
Abstract:
Targeted delivery and controlled release of oligonucleotide therapeutics in vivo are essential aspects of an ideal delivery vehicle. Here we demonstrate the synthesis and in vitro/intracellular characterization of silver nanoparticle (SNP) photolabile nucleic acid conjugates, with the aim of developing a nanoparticulate platform for inducible gene silencing. Due to unique size related properties, nanostructures are being increasingly utilized for intracellular diagnostics and delivery applications. While most nanoscale delivery platforms are polymeric in composition, studies of metallic nanoparticles have highlighted their suitability for delivery of therapeutic agents such as antisense oligonucleotides [1]. The potential benefits of noble metal nanoparticles in delivery applications include tunable size and shape, ease of bulk synthesis and functionalization via ‘wet chemistry’ techniques, and enhanced stability of tethered DNA [2]. Silver is one of the best surface-enhancing substrates available for nanostructure synthesis [3]. SNP composites afford external control over surface-tethered drug release via external triggers.
APA, Harvard, Vancouver, ISO, and other styles
9

Manoharan, Muthiah. "Conjugation strategies for systemic delivery of RNAi drugs." In XVIth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2014. http://dx.doi.org/10.1135/css201414048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Krasnoshtanova, Alla, and Elisaveta Borovkova. "OBTAINING NUCLEIC ACID PREPARATIONS AND THEIR HYDROLYSATES FROM BIOMASS OF METHANE-OXIDIZING BACTERIA." In GEOLINKS Conference Proceedings. Saima Consult Ltd, 2021. http://dx.doi.org/10.32008/geolinks2021/b1/v3/14.

Full text
Abstract:
"Due to the unfavourable environmental, social and economic situation, the need for the treatment of oncological diseases and diseases associated with impaired activity of the immune system is increasing. A lot of these drugs are made on the basis of nucleic acid components, the industrial production of which is practically non-existent in Russia. Therefore, a task of current interest is to develop the basis of the technology for obtaining components of nucleic acids, which can be widely used in medicine as immunomodulatory, wound-healing, antiviral, and diagnostic medicine, as well as for cancer treatment. Most of the described in literature methods of isolating nucleic acid components from plant, animal and microbial raw materials are based on the use of toxic and expensive organic solvents, that’s why it is impossible to apply these methods outside of laboratory conditions. The most promising source of raw materials for nucleic acids is the biomass of microorganisms (yeast and bacteria) from biomass, since the use of such source makes it possible to quickly obtain a large enough amount of biomass, and, consequently, a larger amount of nucleic acids. This allows obtaining DNA in addition to RNA. RNA and DNA substances can be used to obtain nucleosides and nitrogenous bases, which are also widely used in medicine. The purpose of these studies was to select the conditions for the extraction of RNA and DNA from the biomass of methane-oxidizing bacteria in one technological cycle, as well as to compare the efficiency of alkaline and acid hydrolysis of microbial RNA and DNA. The need for a two-stage extraction of nucleic acids from the biomass of methane-oxidizing bacteria in order to separately extract RNA and DNA was Substantiated. It was ascertained that at the first stage of extraction at a temperature of 90 ° C, pH 9.0 for 90 min, at least 85% of RNA is extracted. After the separation of the extract by centrifugation, the partially denuclearized biomass must be re-processed under the same conditions in order to extract DNA by at least 83%. The modes of concentration of RNA and DNA solutions by ultrafiltration were selected. It was found that in order to achieve effective deposition of nucleic acids at the isoelectric point, the concentration of the RNA solution must be carried out on the UPM-10 membrane at the concentration degree of 7, and the DNA solution on the UPM-100 membrane at the concentration degree 6. The dynamics of decomposition of nucleic-protein complexes in the medium of monoammonium phosphate was investigated. It was shown that the transition of NA into solution by at least 80% is achieved at a monoammonium phosphate concentration of 1.7 M, a temperature of 55 ° C for 90 min. The use of 5-fold washing of oligonucleotide substances with acidified water (pH 2.0) to remove excess mineral impurities was substantiated. А comparative assessment of acid and alkaline hydrolysis of RNA and DNA was carried out in order to obtain derivatives of nucleic acids."
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nucleic acid drug' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography